Although clinical outcomes with sacituzumab govitecan have been promising in patients with endometrial cancer (39), Dato-DXd may offer an even more effective and potentially less toxic alternative as a TROP2-targeted ADC. The gene discussed is TACSTD2; the disease is endometrial cancer.